New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
16:43 EDTAERIAerie Pharmaceuticals reports Q2 EPS (49c), consensus (34c)
News For AERI From The Last 14 Days
Check below for free stories on AERI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
06:10 EDTAERIAerie Pharmaceuticals receives $125M investment from Deerfield Management
Subscribe for More Information
06:05 EDTAERIAerie Pharmaceuticals issues $125M in convertible notes to Deerfield Management
Subscribe for More Information
September 5, 2014
06:28 EDTAERIAerie Pharmaceuticals to host investor day
Subscribe for More Information
September 3, 2014
07:34 EDTAERIAerie Pharmaceuticals initiates Phase 3 registration trial of Rhopressa
Aerie Pharmaceuticals announced that on August 29, dosing commenced of the first patients enrolled in the company’s Phase 3 registration trial in Canada of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure in patients with glaucoma or ocular hypertension. The study, named “Rocket 3,” is designed to evaluate safety and tolerability of Rhopressa in patients over a 12 month period and is part of a broad Phase 3 program being conducted by Aerie. The company recently announced the commencement of two Phase 3 trials in the United States, “Rocket 1” and “Rocket 2,” which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa. Pending progress of the Rhopressa Phase 3 program and regulatory approvals, Aerie intends to commercialize Rhopressa in North American markets with its own sales force and will seek commercialization partners in other key territories, including Japan and possibly Europe. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use